Alaunos Therapeutics, INC

Alaunos Therapeutics announced new preclinical statistical analysis of ALN1003 in mice, showing reduced liver weight adjusted for body fat, consistent with other positive liver-related biomarkers.

Alaunos Therapeutics announced integrated preclinical results for ALN1003, an investigational oral drug for obesity and metabolic disorders, showing positive effects in mouse studies.

Alaunos Therapeutics announced updated preclinical data for its investigational oral metabolic therapeutic candidate, ALN1003, showing positive effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity mouse models.

Alaunos Therapeutics has been notified by Nasdaq of non-compliance with minimum stockholders' equity requirements.

Alaunos Therapeutics announced positive preclinical proof-of-concept data for its lead small-molecule drug candidate, ALN1003, for obesity and metabolic disorders.

Alaunos Therapeutics announced the termination of its financial advisor, adopted new bylaws, and reported encouraging preclinical data for its obesity program, while also highlighting an urgent need for additional financing.

Alaunos Therapeutics reports Q1 2026 net loss of $1.0 million while highlighting preclinical progress for its obesity program, ALN1003.

Alaunos Therapeutics reports a net loss and limited cash runway into Q1 2026, with new existential risks from the ongoing U.S. government shutdown impacting its ability to raise capital and maintain Nasdaq compliance.

Alaunos Therapeutics secured $3.26 million in financing and pivoted to an obesity program, but faces Nasdaq delisting and going concern doubts.

Alaunos Therapeutics reports Q1 2025 results, highlighting strategic reprioritization, ongoing small molecule obesity program development, and substantial doubt about its ability to continue as a going concern.

Alaunos Therapeutics announced its Q3 2024 results, highlighting a strategic reprioritization, the wind-down of its TCR-T program, and the evaluation of a small molecule oral obesity treatment program.

Alaunos Therapeutics reported its Q2 2024 financial results while undergoing a strategic reprioritization and cost-reduction efforts.

Alaunos Therapeutics, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.

Alaunos Therapeutics reports positive preclinical data for its obesity program ALN1003 but faces substantial doubt about its ability to continue as a going concern and Nasdaq delisting risk.

Alaunos Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include information on directors, executive officers, corporate governance, and executive compensation.

Alaunos Therapeutics pivots to preclinical obesity drug development while exploring strategic alternatives after halting TCR-T clinical programs.

Alaunos Therapeutics has ceased development of its clinical programs and reduced its workforce by 95% as it explores strategic alternatives due to substantial costs and a challenging financing environment.

Michael Allen Jerman, a Director of Alaunos Therapeutics, Inc., received 8,138 shares of common stock on July 23, 2026.

Robert W Postma, a Director of Alaunos Therapeutics, Inc., received 8,463 shares of common stock on July 23, 2026.

Alaunos Therapeutics CEO Holger Weis acquired 3,880 shares of common stock for $2.26 per share, issued in lieu of net salary.

Alaunos Therapeutics CEO Holger Weis acquired 7,761 shares of common stock for $2.26 per share, totaling $17,540.76, as part of a salary payment.

Alaunos Therapeutics CEO Holger Weis acquired 3,700 shares of common stock for $2.37 per share, issued in lieu of net salary.

Director Jaime Vieser acquired 6,515 shares of Alaunos Therapeutics common stock in lieu of board fees.

Alaunos Therapeutics is holding its 2025 Annual Meeting to vote on key proposals including director elections, auditor ratification, executive compensation, a potential reverse stock split, increased share authorization, and an amendment to the equity incentive plan.

Alaunos Therapeutics is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and an amendment to its equity incentive plan.

Alaunos Therapeutics is asking stockholders to vote on key proposals at its upcoming annual meeting, including a reverse stock split and an increase in authorized shares.

Alaunos Therapeutics is asking stockholders to approve a reverse stock split and an increase in authorized shares at its upcoming annual meeting to maintain Nasdaq listing and provide financial flexibility.

Alaunos Therapeutics, Inc. filed an S-1 for the resale of shares by Mast Hill Fund, L.P., outlining a potential $25 million equity financing and its strategic pivot to a preclinical oral obesity program.

A group of investors led by Adrian Price has proposed a $7 million private placement in Alaunos Therapeutics, seeking Board engagement and a director appointment, with threats of further action if ignored.

A group of investors led by Adrian Price has proposed a $7 million private placement in Alaunos Therapeutics, Inc., seeking Board engagement and a director appointment.

A group of shareholders, led by Adrian Price, has requested the appointment of Gerald W. Bruce to the Board of Directors of Alaunos Therapeutics, Inc. to enhance shareholder value.

A group of 17 shareholders, led by Adrian Price, has filed an amended Schedule 13D, signaling their intent to engage with Alaunos Therapeutics' Board to enhance shareholder value.

A group of 18 individuals has collectively acquired an 8.6% stake in Alaunos Therapeutics, Inc. and intends to engage with the Board to discuss shareholder value creation and strategic acquisitions.

PMGC Capital LLC and PMGC Holdings Inc. have fully divested their holdings in Alaunos Therapeutics, Inc. common stock.

Strategic EP, LLC has reported a complete divestment of its beneficial ownership in Alaunos Therapeutics, Inc., now holding 0% of the common stock as of October 14, 2025.

Strategic EP, LLC has reported a 6.8% beneficial ownership stake in Alaunos Therapeutics, Inc., alongside a standstill agreement that limits its influence.

MSD Partners, MSD Credit Opportunity Master Fund, and Gregg R. Lemkau have filed an Amendment No. 5 to Schedule 13G, disclosing that they no longer beneficially own any shares of Alaunos Therapeutics, Inc. common stock.